Novartis Weighs US Buildout And Rhapsido Launch In Growth Outlook
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…